Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $93.6 million.

  • Rocket Pharmaceuticals' Cash from Investing Activities rose 1862.29% to $93.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.5 million, marking a year-over-year increase of 242.94%. This contributed to the annual value of $131.7 million for FY2024, which is 23430.34% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Cash from Investing Activities stood at $93.6 million, which was up 1862.29% from $31.8 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Cash from Investing Activities high stood at $93.6 million for Q3 2025, and its period low was -$140.8 million during Q4 2023.
  • Moreover, its 5-year median value for Cash from Investing Activities was $23.5 million (2022), whereas its average is $2.7 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 100804.05% in 2021, then crashed by 74388.64% in 2022.
  • Over the past 5 years, Rocket Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $16.9 million in 2021, then plummeted by 743.89% to -$108.6 million in 2022, then decreased by 29.67% to -$140.8 million in 2023, then skyrocketed by 73.1% to -$37.9 million in 2024, then soared by 347.2% to $93.6 million in 2025.
  • Its Cash from Investing Activities was $93.6 million in Q3 2025, compared to $31.8 million in Q2 2025 and -$58.0 million in Q1 2025.